Although monotherapy with the sMIC-neutralizing antibody B10G5 and ALT-803 elicited survival benefits in comparison to control treatment, combined therapy further significantly prolonged survival in comparison to monotherapy in two independent tumor transplants (p < 0.05 and p < 0.0001 respectively, Figure 1b and 1d). The gene discussed is GPT; the disease is neoplasm.